Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?

Teams from University of California San Diego and City of Hope debate whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable NSCLC.

EP: 1.Introduction of the UCSD vs City of Hope Face-Off

EP: 2.Advanced ALK-Rearranged NSCLC

EP: 3.Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN

EP: 4.CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC

EP: 5.Where Does the POSEIDON Regimen Fit in the NSCLC Treatment Landscape?

EP: 6.A Case of Metastatic ROS1 Fusion-Positive NSCLC

EP: 7.Patient Profile: EGFRm Post-Osimertinib

EP: 8.Patient Case: PD-L1 Negative NSCLC

EP: 9.KRAS Patient Case

EP: 10.Neoadjuvant Chemoimmunotherapy for Resectable NSCLC

Now Viewing

EP: 11.Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?

EP: 12.Treatment Options for Patients with EGFRm: EGFR TKI + Chemotherapy

EP: 13.Treatment Options for Patients with EGFRm: EGFR TKI

EP: 14.Face-Off: Award Ceremony

Recent Videos